European Society of Toxicology In Vitro > News > Using NAMs in Risk Assessment: September 2022
26 September 2022

Using NAMs in Risk Assessment: September 2022

Friday, September 30, 2022
10:00 – 11:30 AM EDT

Presenters:
Katie Paul-Friedman, PhD, US EPA: Expectations for new approach methods performance in predicting effects in repeat dose animal studies
George E. N. Kass, PhD, European Food Safety Authority (EFSA): EFSA’s roadmap on NAMs and related case studies

Registration is open!

Expectations for new approach methods performance in predicting effects in repeat dose animal studies

Katie Paul Friedman, PhD, Center for Computational Toxicology and Exposure, Office of Research and Development, US EPA

Building scientific confidence in new approach methodologies (NAMs) for regulatory toxicology may include a comparison to in vivo results. This presentation overviews work to characterize benchmark expectations for NAM performance in predicting systemic and organ-level effects in repeat dose studies of adult animals using data curated into the Toxicity Reference Database. The reproducibility, variability, and differences in systemic and organ-level findings (liver, kidney, stomach, spleen, thyroid, and adrenal) in repeat dose studies, using lowest effect level (LELs) for body and/or organ weight, as well as gross and/or histopathological changes, were investigated.  

Quantitative variability in LELs was examined with multilinear regression modeling, using study descriptors as covariates to estimate total variance, mean square error (MSE), and root residual mean square error (RMSE) in systemic and organ LELs. The MSE values suggest study descriptors accounted up to 70% of total variance in organ and systemic LELs, and that RMSE ranged 0.4 – 0.6 log10-mg/kg/day.  

A quantitative structure activity relationship model for repeat dose point-of-departure (POD) estimates was constructed that used this RMSE estimate of variability to construct a POD distribution and 95% confidence interval for each POD prediction. 

Qualitative variability was further examined. The concordance of organ-level findings in replicate studies, defined by chemical only, chemical and species, and chemical and study type, ranged 39 – 88%. Odds ratios indicated it is unlikely to observe organ effects in a chronic study if the chemical was negative in a subchronic study. 

Overall, quantitative and qualitative variability in repeat dose LEL values suggests that a good NAM might predict systemic or organ LELs within ± 1 log10-mg/kg/day with accuracy approaching 70%. Organ level findings are most reproducible within-species, and a subchronic study is likely to identify effects in organs that demonstrate effects in the chronic study. This abstract does not necessarily reflect U.S. EPA policy. 

EFSA’s roadmap on NAMs and related case studies

George E. N. Kass, PhD, European Food Safety Authority (EFSA)

The European Food Safety Authority (EFSA) carries out risk assessments in relation to food and feed safety, and in the case of chemicals, provides health-based guidance values. These are mostly derived from in vivo animal toxicity data, using traditional endpoint measurements. However, EFSA is following closely and investing in the development and regulatory application of new methodologies and tools, the so-called New Approach Methodologies or NAM as part of its scientific strategy. The use of NAMs in regulatory chemical risk assessment has so far been very limited in EFSA. To overcome these challenges and generate opportunities for NAMs in regulatory chemical risk assessment, EFSA launched a contract to develop a roadmap for action on NAMs to reduce animal testing. The roadmap aims to define EFSA’s priorities for the incorporation of NAMs as well as to inform a multiannual strategy for increasing the use of NAMs in human health risk assessment to minimise the need for animal-based verification studies. Ultimately, it envisions that by 2027 the majority of EFSA’s requests for additional data will be based on NAMs. The presentation will provide an overview of the roadmap on NAMs and some of the activities currently ongoing in the context of its implementation.  

Related content

Congress banners for social media presentations

Download your ESTIV 2022 Congress banner for the social media presentations

Be aware of scammers…..

  • News

Please be aware, that ESTIV and many other EU-based societies are currently facing the incased activity of scams and fraudulent e-mails requesting bank transfers to various accounts. ….

Call for papers into the special Issue of Toxicology in Vitro- ESTIV 2022: Key enabling non-animal technologies for research, education, and testing

  • News

All authors who submitted their abstract(s) to the ESTIV 2022 congress have now the possibility to submit their work into the
Special Issue of Toxicology in Vitro: ESTIV 2022

Gold Sponsor

Silver Sponsor

Corporate Members

Affiliated Societies

Memorandum of Understanding